CRISPR Therapeutics (CRSP) News Today $38.67 +1.27 (+3.40%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period 2 Beaten-Down Stocks With Incredible Upside PotentialApril 30 at 5:14 AM | fool.comCathie Wood’s ARK shifts focus, buys AMD stock and trims CRISPRApril 29 at 8:42 PM | investing.comBarclays PLC Trims Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Barclays PLC lowered its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 21.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 102,058 shares of the company's stock after selling 27,790 shares during the quarter. Barclays PLC ownApril 29 at 3:50 AM | marketbeat.comRaymond James Financial Inc. Invests $3.23 Million in CRISPR Therapeutics AG (NASDAQ:CRSP)Raymond James Financial Inc. purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 82,095 shares of the company'sApril 29 at 3:50 AM | marketbeat.comT. Rowe Price Investment Management Inc. Buys 1,074,238 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)T. Rowe Price Investment Management Inc. boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 39.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,811,708 shares of theApril 27 at 5:51 AM | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by XTX Topco LtdXTX Topco Ltd decreased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 70.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,919 shares of the company's stock after selling 21,103 shApril 26, 2025 | marketbeat.comCRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?April 25, 2025 | msn.comLegal & General Group Plc Has $3.85 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Legal & General Group Plc reduced its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 8.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 97,804 shares of the company's stock after selling 9,121 sharesApril 25, 2025 | marketbeat.comPrediction: 1 Biotech Stock That Could Surpass Pfizer by 2030April 24, 2025 | 247wallst.com‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO CapitalApril 23, 2025 | finance.yahoo.comCapital International Investors Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Capital International Investors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 10.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 8,743,523 shares of the company's stock after purchasing an additional 816,789 shaApril 21, 2025 | marketbeat.comCapital International Sarl Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Capital International Sarl raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 186,920 shares of the company's stock after buying an additionalApril 21, 2025 | marketbeat.comLeerink Partnrs Issues Negative Outlook for CRSP EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities researchers at Leerink Partnrs cut their Q1 2025 earnings estimates for CRISPR Therapeutics in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1April 20, 2025 | marketbeat.comWells Fargo & Company MN Buys 17,094 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Wells Fargo & Company MN increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 8.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 220,123 shares of the company's stock after purchasing an additionalApril 20, 2025 | marketbeat.comJump Financial LLC Has $5.48 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Jump Financial LLC raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 174.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,280 shares of the company's stock after acquiring an addApril 19, 2025 | marketbeat.comAdvisory Services Network LLC Lowers Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Advisory Services Network LLC decreased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 43.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 10,057 shares of the company's stock after selling 7,629 shares during the periodApril 19, 2025 | marketbeat.comCrispr Therapeutics price target lowered to $80 from $86 at BofAApril 17, 2025 | markets.businessinsider.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Geode Capital Management LLCGeode Capital Management LLC decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,000,868 shares of the company'April 17, 2025 | marketbeat.comCRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last WeekApril 17, 2025 | finance.yahoo.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 4% - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 4% - Time to Sell?April 16, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Reynders McVeigh Capital Management LLCReynders McVeigh Capital Management LLC decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 97,687 shares of the company's stockApril 15, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,735,998 shares of the company's stock aftApril 13, 2025 | marketbeat.com3 Magnificent Stocks That Could Double or More by 2030April 12, 2025 | fool.comBrokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Price Target at $73.11Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have been assigned an average rating of "Hold" from the twenty-one analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, nine have given a hold recommendatioApril 12, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for CRISPR Therapeutics (NASDAQ:CRSP)Needham & Company LLC restated a "buy" rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday.April 11, 2025 | marketbeat.comCRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should KnowApril 11, 2025 | finance.yahoo.comExodusPoint Capital Management LP Buys New Shares in CRISPR Therapeutics AG (NASDAQ:CRSP)ExodusPoint Capital Management LP bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 47,840 shares of the company's stock, valued at approximately $1,883,000. ExodusPApril 11, 2025 | marketbeat.comCalifornia Public Employees Retirement System Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)California Public Employees Retirement System lessened its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 10.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 95,948 shares of the company's stock after selliApril 11, 2025 | marketbeat.comCould CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?April 11, 2025 | fool.comCRISPR Therapeutics (NASDAQ:CRSP) Hits New 52-Week Low - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week Low - Should You Sell?April 9, 2025 | marketbeat.comNorges Bank Makes New $17.46 Million Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)Norges Bank acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 443,536 shares of the company's stock, valued at approximately $17,458,000. Norges Bank owned about 0.52% of CRISPApril 9, 2025 | marketbeat.comLPL Financial LLC Has $5.89 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)LPL Financial LLC boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 39.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 149,726 shares of the company's stock after buying an additional 42,232 shares during the period.April 9, 2025 | marketbeat.comCRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)April 8, 2025 | seekingalpha.comCRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of "Hold" by BrokeragesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been assigned a consensus rating of "Hold" from the twenty-one research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendationApril 8, 2025 | marketbeat.com4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall StreetApril 7, 2025 | fool.comCRISPR Therapeutics (NasdaqGM:CRSP) Sees 12% Weekly Dip Following COO ResignationApril 5, 2025 | finance.yahoo.comCrispr Therapeutics granted orphan status for follicular lymphoma treatmentApril 5, 2025 | markets.businessinsider.comCRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should KnowApril 5, 2025 | msn.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 8.7% - Should You Sell?CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 8.7% - What's Next?April 4, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Reaches New 1-Year Low - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Sets New 1-Year Low - Should You Sell?April 4, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Stake Boosted by Pictet Asset Management Holding SAPictet Asset Management Holding SA lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 272,704 shares of the company's stock after purchasiApril 4, 2025 | marketbeat.comKLP Kapitalforvaltning AS Purchases Shares of 16,100 CRISPR Therapeutics AG (NASDAQ:CRSP)KLP Kapitalforvaltning AS acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 16,100 shares of the company's stock, valued at approximately $634April 4, 2025 | marketbeat.comCRISPR Therapeutics AG to Present at 24th Annual Needham Virtual Healthcare ConferenceApril 3, 2025 | gurufocus.comCRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 3, 2025 | globenewswire.comCRISPR Therapeutics set to snap six straight sessions of lossesApril 3, 2025 | msn.comCRISPR Therapeutics snaps six straight sessions of lossesApril 3, 2025 | msn.comCRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month Low - What's Next?CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week Low - Here's WhyApril 2, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 8.7% - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 8.7% - Here's What HappenedApril 1, 2025 | marketbeat.comBlair William & Co. IL Lowers Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Blair William & Co. IL trimmed its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 6.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 114,400 shares of the company's stock after selling 7,509 shares during the peApril 1, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by NEOS Investment Management LLCNEOS Investment Management LLC lowered its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 30.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,231 shares of the company's stoApril 1, 2025 | marketbeat.com Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Media Mentions By Week CRSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.790.85▲Average Medical News Sentiment CRSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼1011▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Exelixis News Neurocrine Biosciences News Qiagen News Repligen News Bio-Techne News Revolution Medicines News Halozyme Therapeutics News ADMA Biologics News Krystal Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRSP Stock Free CRSP Stock Alerts